Author

A. Farkkila

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Research Focus:differential expression· 3 Approach:statistical model· 3 Research Focus:cell-cell communication· 2 Approach:deep learning· 2 Research Focus:drug response / drug discovery· 2 Research Focus:gene regulatory network inference· 2 Assay:spatial transcriptomics· 2

Frequent Co-Authors

J. Hynninen· 3 shared J. Oikkonen· 3 shared S. Hautaniemi· 3 shared Y. Li· 3 shared A. Szabo· 2 shared A. Vaharautio· 2 shared A. Virtanen· 2 shared D. Afenteva· 2 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

J. Hynninen

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Multi-Omics Analysis Reveals the Attenuation of the Interferon Pathway as a Driver of Chemo-Refractory Ovarian Cancer

D. Afenteva, R. Yu, A. Rajavuori, M. Salvadores, I.-M. Launonen, K. Lavikka, K. Zhang, G. Marchi, S. Jamalzadeh, V.-M. Isoviita, Y. Li, G. Micoli, E. P. Erkan, M. M. Falco, D. Ungureanu, , S. Hautaniemi

The paper identifies reduced IFN-I pathway activity as a driver of chemo-refractory ovarian cancer using multi-omics analysis in a clinical trial cohort.

bioRxiv · Mar 28, 2024Cancer Biology

Chemotherapy induces myeloid-driven spatial T-cell exhaustion in ovarian cancer

I.-M. P. Launonen, E. P. Erkan, I. Niemiec, A. Junquera, M. Hincapie-Otero, D. Afenteva, Z. Liang, M. Salko, A. Szabo, F. Perez-Villatoro, M. M. Falco, Y. Li, G. Micoli, A. Nagaraj, U.-M. Haltia, , A. Farkkila

This study shows chemotherapy causes myeloid-driven spatial T-cell exhaustion in ovarian cancer by altering immune cell states and interactions, suggesting new immunotherapy approaches.

bioRxiv · Mar 19, 2024 · PreprintCancer Biology

Single-cell spatial atlas of tertiary lymphoid structures in ovarian cancer

J. Sarkkinen, A. Junquera Mencia, E. Anttila, A. Szabo, F. Perez, I.-M. Launonen, A. Laury, J. Casado, E. Kekalainen, A. Farkkila

This study creates a single-cell spatial atlas of tertiary lymphoid structures (TLSs) in ovarian cancer, revealing distinct TME composition, gene expression profiles, and cell-cell interactions associated with TLSs.

bioRxiv · May 16, 2023 · PreprintCancer Biology

Optimized detection of allelic imbalances specific for homologous recombination deficiency improves the prediction of clinical outcomes in cancer

F. Perez-Villatoro, J. Oikkonen, J. Casado, A. Chernenko, D. C. Gulhan, M. Tumiati, Y. Li, K. Lavikka, S. Hietanen, J. Hynninen, U.-M. Haltia, J. S. Tyrmi, H. Laivuori, P. Konstantinopoulos, S. Hautaniemi, , A. Farkkila

The paper develops a tumor-specific method to detect allelic imbalances for HRD prediction, showing improved clinical outcome prediction in ovarian and breast cancers.

bioRxiv · Aug 19, 2021Cancer Biology

Polymerase Theta Inhibition Kills Homologous Recombination Deficient Tumors

J. Zhou, C. Gelot, C. Pantelidou, A. Li, H. Yucel, R. E. Davis, A. Farkkila, B. Kochupurakkal, A. Syed, G. I. Shapiro, J. A. Tainer, B. S. Blagg, R. Ceccaldi, A. D. D'Andrea

The paper identifies Novobiocin as a POLθ inhibitor that selectively kills HR-deficient tumors, including those resistant to PARP inhibitors.

bioRxiv · May 23, 2020Cancer Biology